Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,455 signal articles · 146 in last 24h · 154,143 total before filter · latest 1h ago
146last 24h
877last 7d
147● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings108M&A126Regulatory21Product21Analyst17
✕ clear all filtersticker: EDSASentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Edesa Biotech Stock Sinks After Fresh Capital Raise
Benzinga35d agoneutral
Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech, Inc. (NASDAQ:EDSA) shares fell nearly 13% in Thursday premarket trading after the company priced a $25 million public stock offering. Edesa Biotech shares fell 18.27% to $4.70 in Wednesday’s after-market session, putting the stock on traders’ radars. The move followed the company’s Q3 earnings release, which came out four days earlier, according to Benzinga’s after-hours movers recap. What Is Edesa Biotech’s Financing Deal? Edesa is raising fresh capital via an equity offering of

Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
Insider Monkey157d agoneutral
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment

Edesa Biotech Inc. (NASDAQ:EDSA) is one of the 10 Unstoppable Stocks That Could Double Your Money. Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollment for its Phase 2 clinical study of EB06, which is a treatment for moderate-to-severe nonsegmental vitiligo, is […]